Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles

Bibliography

• Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007;369(9580):2196-210
   PubMed Web of Science ®Google Scholar
• Boisier P, Nicolas P, Djibo S, Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007;44:657-63
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization. Wkly Epidemiol Rec 2001;37:281-8
   Google Scholar
• WHO. World Health Organization. Wkly Epidemiol Rec 2009;84:173-84
   PubMedGoogle Scholar
• Popovic T, Sacchi CT, Reeves MW, Neisseria meningitidis serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 2000;6:428-9
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009;27(Suppl 2):B51-63
   PubMed Web of Science ®Google Scholar
• Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969;129:1367-84
   PubMed Web of Science ®Google Scholar
• Griffiss JM, Brandt BL, Altieri PL, Safety and immunogenicity of group Y and group W135 meningococcal capsular polysaccharide vaccines in adults. Infect Immun 1981;34:725-32
   PubMed Web of Science ®Google Scholar
• Miller E, Salisbury D, Ramsay M. Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001;20 Suppl 1:S58-67
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008;197:737-43
   PubMed Web of Science ®Google Scholar
• Ramsay ME, Andrews NJ, Trotter CL, Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326(7385):365-6
   PubMed Web of Science ®Google Scholar
• de Greeff SC, de Melker HE, Spanjaard L, Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J 2006;25:79-80
   PubMed Web of Science ®Google Scholar
• Fritsche L, Irvine K, Boomer M. Decline in serogroup C meningococccal disease in children aged 0–18 years. N S W Public Health Bull 2005;16:136-7
   Google Scholar
• De Wals P, Coudeville L, Trottier P, Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. Vaccine 2007;25(29):5433-40
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1-21
   PubMedGoogle Scholar
• Launch of meningococcal A conjugate vaccine, Burkina Faso, December 2010. Geneva: World Health Organization, 2010 Available from: http://www.who.int/immunization/newsroom/events/menafrivac/en/. [Last accessed 13 May 2011]
   Google Scholar
• Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7
   PubMed Web of Science ®Google Scholar
• Bai X, Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010;9:1203-17
   PubMed Web of Science ®Google Scholar
• Devoe IW, Gilchrist JE. Release of endotoxin in the form of cell wall blebs during in vitro growth of Neisseria meningitidis. J Exp Med 1973;138:1156-67
   PubMed Web of Science ®Google Scholar
• Guttormsen HK, Wetzler LM, Solberg CO. Humoral immune response to class 1 outer membrane protein during the course of meningococcal disease. Infect Immun 1994;62:1437-43
   PubMed Web of Science ®Google Scholar
• Bjune G, Hoiby EA, Gronnesby JK, Sabine Henry S, Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6
   PubMed Web of Science ®Google Scholar
• Taha MK, Parent du Chatelet I, Sabine Henry S, The control of hyper-endemic serogroup B meningococcal infection in Normandy, France. Programme and abstracts of the 10th European Meningococcal Disease Society Meeting; 17 – 19 June 2009; Manchester, United Kingdom; 2009. p. 32-O017
   Google Scholar
• Sierra GV, Campa HC, Varcacel NM, Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-207; discussion 208–210
   PubMedGoogle Scholar
• de Moraes JC, Perkins BA, Camargo MC, Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8
   PubMed Web of Science ®Google Scholar
• Boslego J, Garcia J, Cruz C, Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 1995;13:821-9
   PubMed Web of Science ®Google Scholar
• Oster P, Lennon D, O'Hallahan J, MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6
   PubMed Web of Science ®Google Scholar
• O'Hallahan J, McNicholas A, Galloway Y, Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease. N Z Med J 2009;122:48-59
   PubMedGoogle Scholar
• Wong S, Lennon D, Jackson C, New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007;26:345-50
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Naess LM, The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 2005;23:2202-5
   PubMed Web of Science ®Google Scholar
• Sacchi CT, Whitney AM, Popovic T, Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-76
   PubMed Web of Science ®Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-18
   PubMed Web of Science ®Google Scholar
• Cartwright K, Morris R, Rumke H, Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-19
   PubMed Web of Science ®Google Scholar
• de Kleijn ED, de Groot R, Labadie J, Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000;18:1456-66
   PubMed Web of Science ®Google Scholar
• van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007;25:2491-6
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R, Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007;14:65-73
   PubMed Web of Science ®Google Scholar
• Sandbu S, Feiring B, Oster P, Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007;14:1062-9
   PubMed Web of Science ®Google Scholar
• Gorringe AR, Taylor S, Brookes C, Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol 2009;16:1113-20
   PubMedGoogle Scholar
• Weynants V, Denoel P, Devos N, Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 2009;77:2084-93
   PubMed Web of Science ®Google Scholar
• Urwin R, Russell JE, Thompson EA, Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design. Infect Immun 2004;72:5955-62
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000;3:445-50
   PubMed Web of Science ®Google Scholar
• Pizza M, Scarlato V, Masignani V, Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000;287:1816-20
   PubMed Web of Science ®Google Scholar
• Jacobsson S, Hedberg ST, Molling P, Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009;27:1579-84
   PubMed Web of Science ®Google Scholar
• Oster P, Toneatto D, Dull P, First use of an investigational meningococcal serogroup B vaccine administered in combination with New Zealand (NZ) strain (NZ98/254) outer membrane vesicles (OMV) in healthy adults. Abstract of Meningitis and Septicaemia in Children and Adults 2009 -Meningitis Research Foundation; 11 – 12 November; London, UK; 2009. p. 52
   Google Scholar
• Esposito S, Vesikari T, Kimura A, Tolerability of a three-dose schedule of an investigational, multicomponent meningococcal serogroup B vaccine and routine infant vaccines in a lot consistency trial. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 168 P182
   Google Scholar
• Fletcher LD, Bernfield L, Barniak V, Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004;72:2088-100
   PubMed Web of Science ®Google Scholar
• Richmond P, Marshall HS, Nissen MD. A randomized, observed-blinded, active control, Phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescent aged 8 to 14 years. The 16th International Pathogenic Neisseria Conference; 7 – 12 September 2008; Rotterdam, The Netherlands; 2008. p. 270 P212
   Google Scholar
• Richmond P, Marshall H, Sheldon E, Safety & immunogenicity of serogroup B Neisseria meningitidis (MnB) rLP2086 vaccine in adults and adolescent subjects: overview of 3 clinical trials. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 37 VW04
   Google Scholar
• Findlow J, Borrow R, Snape MD, Multicenter, open-label, randomized Phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37
   PubMed Web of Science ®Google Scholar
• Snape MD, Dawson T, Oster P, Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-9
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969;129:1307-26
   PubMed Web of Science ®Google Scholar
• Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27 Suppl 2:B112-16
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, Neisseria meningitidis group B correlates of protection and assay standardization– international meeting report Emory University, Atlanta, Georgia, United States, 16–17 March 2005. Vaccine 2006;24:5093-107
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE, Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7
   PubMed Web of Science ®Google Scholar
• Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection – serum bactericidal antibody activity. Vaccine 2005;23:2222-7
   PubMed Web of Science ®Google Scholar
• Borrow R, Aaberge IS, Santos GF, Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005;12:970-6
   PubMedGoogle Scholar
• Zollinger WD, Mandrell RE. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun 1983;40:257-64
   PubMed Web of Science ®Google Scholar
• Mandrell RE, Zollinger WD. Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants. J Immunol 1982;129:2172-8
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Brunelli B, NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med 2002;195:1445-54
   PubMed Web of Science ®Google Scholar
• Comanducci M, Bambini S, Caugant DA, NadA diversity and carriage in Neisseria meningitidis. Infect Immun 2004;72:4217-23
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J, Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine. Clin Vaccine Immunol 2010;17:919-29
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107:19490-5
   PubMed Web of Science ®Google Scholar
• Metruccio MM, Pigozzi E, Roncarati D, A novel phase variation mechanism in the meningococcus driven by a ligand-responsive repressor and differential spacing of distal promoter elements. PLoS Pathog 2009;5:e1000710
   PubMed Web of Science ®Google Scholar
• Capecchi B, Adu-Bobie J, Di Marcello F, Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 2005;55:687-98
   PubMed Web of Science ®Google Scholar
• Mazzon C, Baldani-Guerra B, Cecchini P, IFN-gamma and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin A. J Immunol 2007;179:3904-16
   PubMed Web of Science ®Google Scholar
• Litt DJ, Savino S, Beddek A, Putative vaccine antigens from Neisseria meningitidis recognized by serum antibodies of young children convalescing after meningococcal disease. J Infect Dis 2004;190:1488-97
   PubMed Web of Science ®Google Scholar
• Biolchi A, Pigozzi E, Boccadifuoco G, In vitro levels of NadA expression may underestimate the potential effectiveness of immune responses against nadA in vivo. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 172 P189
   Google Scholar
• Masignani V, Comanducci M, Giuliani MM, Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99
   PubMed Web of Science ®Google Scholar
• Schneider MC, Prosser BE, Caesar JJ, Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 2009;458:890-3
   PubMed Web of Science ®Google Scholar
• Beernink PT, Welsch JA, Harrison LH, Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis 2007;195:1472-9
   PubMed Web of Science ®Google Scholar
• Madico G, Welsch JA, Lewis LA, The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10
   PubMed Web of Science ®Google Scholar
• Bambini S, Muzzi A, Olcen P, Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009;27:2794-803
   PubMed Web of Science ®Google Scholar
• Beernink PT, Leipus A, Granoff DM. Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol 2006;13:758-63
   PubMedGoogle Scholar
• Murphy E, Andrew L, Lee KL, Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200:379-89
   PubMed Web of Science ®Google Scholar
• Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine 2010;28:2122-9
   PubMed Web of Science ®Google Scholar
• Serruto D, Spadafina T, Ciucchi L, Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci USA 2010;107:3770-5
   PubMed Web of Science ®Google Scholar
• Lucidarme J, Comanducci M, Findlow J, Characterization of fHbp, nhba (gna2132), nadA, porA, sequence type (ST), and genomic presence of IS1301 in group B meningococcal ST269 clonal complex isolates from England and Wales. J Clin Microbiol 2009;47:3577-85
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Adu-Bobie J, Comanducci M, A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006;103:10834-9
   PubMed Web of Science ®Google Scholar
• Biolchi A, Kleinschmidt A, Boccadifuoco G, Evaluation of the contribution of protein antigen NHBA to bactericidal antibody responses in sera from human vaccinees enrolled in clinical trials. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 171 P188
   Google Scholar
• Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-23
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Biolchi A, Serruto D, Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010;28:5023-30
   PubMed Web of Science ®Google Scholar
• Cooper CL, Angel JB, Seguin I, CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008;46:1310-14
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2:197-203
   PubMedGoogle Scholar
• Guideline on adjuvants in vaccines for human use. EMEA/CHMP/VEG/134716/2004. London: European Medicines Agency, 2005 Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003809. [Last accessed 13 May 2011]
   Google Scholar
• Moller AS, Bjerre A, Brusletto B, Chemokine patterns in meningococcal disease. J Infect Dis 2005;191:768-75
   Google Scholar
• Wang X, Cohn A, Comanducci M, Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 122 P089
   Google Scholar
• Findlow J, Lucidarme J, Comanducci M, Characterisation of fhbp, nhba, nadA, porA and sequence type in meningococcal group B case isolates collected in England and Wales in the epidemiological year 2007/2008, and the potential coverage of an investigational group B vaccine. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. OM09
   Google Scholar
• Heike C, Comanducci M, Muzzi A, Diversity of the Novartis investigational vaccine in German invasive meningococcal isolates 2007/2008. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 176 P197
   Google Scholar
• Dull P, Pizza M, Toneatto D, Early clinical development of a novel, multicomponent meningococcal serogroup B vaccine (4CMenB).. The 17th International Pathogenic Neisseria Conference; 11 – 16 September 2010; Banff, Canada; 2010. p. 36 VW01
   Google Scholar
• Borrow R. Advances in the MenB vaccine development. Program and abstracts of the 26th annual Meeting of the European Society for Paediatric Infectious Diseases; 13 – 17 May 2008; Graz, Austria; 2008. p. 8
   Google Scholar
• Brunelli B, Del Tordello E, Palumbo E, Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2010;29:1072-81
   PubMed Web of Science ®Google Scholar
• Novartis. Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents. ClinicalTrials.gov NCT00297817. Available from: http://clinicaltrials.gov/ct2/show/NCT00297817?term=NCT00297817&rank=1
   Google Scholar
• Oster P, Keyserling H, Ympa E, First use in adolescents of an investigational recombinant meningococcal B vaccine developed by reverse vaccinology. Abstract of Meningitis and Septicaemia in Children and Adults 2009 -Meningitis Research Foundation; 11 – 12 November; London, UK; 2009. p. 53
   Google Scholar
• Novartis. Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules. ClinicalTrials.gov NCT00661713. Available from: http://clinicaltrials.gov/ct2/show/NCT00661713?term=NCT00661713&rank=1
   Google Scholar
• Novartis. Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. ClinicalTrials.gov NCT01148524. Available from: http://clinicaltrials.gov/ct2/show/NCT01148524?term=NCT01148524&rank=1
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use-Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:273
   PubMedGoogle Scholar
• The U.K. Green Book. Immunisation against infectious disease. Available from: http://www.dh.gov.uk/en/Publichealth/Immunisation/Greenbook/index.htm.2006
   Google Scholar
• Boutet R, Stuart JM, Jones DM, Kaczmarski EB. Prevention of meningococcal infection in laboratory workers – an audit of practice in England and Wales. Commun Dis Public Health 2001;4:130-2
   PubMedGoogle Scholar
• Novartis. Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults. ClinicalTrials.gov NCT00560313. Available from: http://clinicaltrials.gov/ct2/show/NCT00560313?term=NCT00560313&rank=1
   Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011;18:483-6
   PubMed Web of Science ®Google Scholar
• Novartis: Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants. ClinicalTrials.gov NCT00657709. Available from: http://clinicaltrials.gov/ct2/show/NCT00657709?term=NCT00657709&rank=1
   Google Scholar
• Vesikari T, Esposito S, Prymula R, Use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in a clinical trial in 3630 infants. Arch Dis Child 2011;96(3):11-16
   Google Scholar
• Novartis. Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers. ClinicalTrials.gov NCT00847145. Available from: http://clinicaltrials.gov/ct2/show/NCT00847145?term=NCT00847145&rank=1
   Google Scholar
• Novartis. One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age. ClinicalTrials.gov NCT01139021. Available from: http://clinicaltrials.gov/ct2/show/NCT01139021?term=NCT01139021&rank=1
   Google Scholar
• Novartis. Novartis Vaccine and Diagnostics Carriage Trial. ClinicalTrials.gov NCT01214850. Available from: http://clinicaltrials.gov/ct2/show/NCT01214850?term=NCT01214850&rank=1
   Google Scholar
• Hill A. Novartis submits meningococcal vaccine Bexsero for European approval. 2010. Available from: http://www.inpharm.com/news/101223/novartis-meningococcal-vaccine-bexsero. [Last accessed 13 May 2011]
   Google Scholar
• Novartis. Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study. ClinicalTrials.gov NCT00381615. Available from: http://clinicaltrials.gov/ct2/show/NCT00381615?term=NCT00381615&rank=1
   Google Scholar
• Health Protection Agency, United Kingdom. Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults. ClinicalTrials.gov NCT00962624. Available from: http://clinicaltrials.gov/ct2/show/NCT00962624?term=NCT00962624&rank=1
   Google Scholar
• Novartis. Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine. ClinicalTrials.gov NCT01026974. Available from: http://clinicaltrials.gov/ct2/show/NCT01026974?term=NCT01026974&rank=1
   Google Scholar
• Novartis. Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine. ClinicalTrials.gov NCT01027351. Available from: http://clinicaltrials.gov/ct2/show/NCT01027351?term=NCT01027351&rank=1
   Google Scholar
• Novartis. Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules ClinicalTrials.gov NCT00721396. Available from: http://clinicaltrials.gov/ct2/show/NCT00721396?term=NCT00721396&rank=1
   Google Scholar